<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04960891</url>
  </required_header>
  <id_info>
    <org_study_id>Non Applicable</org_study_id>
    <nct_id>NCT04960891</nct_id>
  </id_info>
  <brief_title>Managed Access Program Supporting Patient Access to Tebentafusp</brief_title>
  <acronym>Non Applicable</acronym>
  <official_title>A Managed Access Program Which Will Support Patient Access to Tebentafusp Outside of Clinical Trials or Where Tebentafusp is Not Yet Available</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunocore Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinigen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunocore Ltd</source>
  <brief_summary>
    <textblock>
      A managed access program to support patient access to Tebentafusp outside of clinical trials&#xD;
      or to where Tebentafusp is not yet available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Uveal Melanoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tebentafusp</intervention_name>
    <description>Concentrate solution for intravenous infusion</description>
    <other_name>non applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  To be disclosed on a per patient basis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  To be disclosed on a per patient basis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>00441235438600</phone>
    <email>medical.information@immunocore.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

